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One Sentence Summary: Low copy numbers of DEFA1A3 CNVs increases the risk for IgA 
nephropathy development and poor renal survival. 
 
Abstract: IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide 
whose etiology is poorly understood. Although being a major source of genetic variation in the 
human genome, copy number variations (CNVs), particularly the complex multi-allelic ones, are 
poorly studied and understood in terms of their involvement in disease development. Here we 
performed a comprehensive association analysis of DEFA1A3 CNV locus on 8p23.1 in two 
independent IgA nephropathy (IgAN) cohorts of Southern Chinese Han, consisting of a total of 
1189 cases and 1187 healthy controls. We discovered three independent associations within the 
locus: the total copy number of DEFA1A3 (P=3.99×10-9, OR=0.88 per copy) as well as the copy 
numbers of DEFA3 (P=6.55×10-5, OR=0.82) and a noncoding deletion variant (211bp) 
(P=3.50×10-16, OR=0.75) (fixed-effects meta-analysis). While showing very strong association 
with increased risk for IgAN (P=9.56×10-20), the low total copy numbers of the three variants 
(Genetic Score) also showed significant association with poor long-term renal survival of IgAN 
(P=0.03, HR=3.69, after controlling the effects of known prognostic factors) and high serum 
level of galactose-deficient IgA1 (P=0.03).  As a replication, we confirmed the associations of 
DEFA1A3 (P=4.42×10-4, OR=0.82) and DEFA3 copy numbers (P=4.30×10-3, OR=0.74) with 
IgAN in a Caucasian cohort (531 cases and 198 controls).  Interestingly, we also found the 
association of 211bp copy number with membranous nephropathy (P=1.11×10-7, OR=0.74 in 
493 Chinese cases and 500 matched controls), but no associations were found with diabetic 
kidney disease (in 806 Chinese cases and 786 matched controls). By explaining 4.96% of risk 
variance, the DEFA1A3 CNV locus is the strongest genetic susceptibility locus for IgAN 
identified so far and also influences the renal survival of IgAN, supporting the possibility of 
DEFA1A3 being a novel therapeutic target and prognostic biomarker. 
 
[Main Text:] 
Introduction 
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide (1-3). The 
clinicopathologic patterns and the prognosis of IgAN show extremely wide variability, ranging 
from asymptomatic to rapidly progressive forms (4). The pathogenesis of IgAN is not well 
understood, but it’s generally considered to be a complex and multifactorial disorder with both 
genetic and environmental factors contributing to its development (5). Thus far, there have been 
four genome-wide association studies (GWAS) for IgAN, and multiple susceptibility loci have 
been identified (6-9).  However, these GWAS loci can only explain 5% to 7.6% of total disease 
risk (9), and none of them has effect on disease prognosis.  
 
Copy number variations (CNVs) have been shown to be a major source of genetic variation in 
human genome (10, 11) and have significant phenotypic impact by altering gene dosage, 
disrupting coding sequences or perturbing long-range gene regulation (12). Although CNVs have 
been suggested to play important roles in disease development (11, 13, 14), the associations of 
CNVs, particularly the role complex multi-allelic CNVs in complex diseases are poorly studied 
and understood, mainly due to experimental difficulties in measuring the copy number of such 
variants accurately (15). The alpha-defensin locus (DEFA1A3) is one of the complex multi-
allelic CNVs, presented as tandem repeats of a 19kb sequence unit, each of which contains one 
copy ofDEFA1 or DEFA3 (alpha-defensin 1 or 3 that differ by a single non-synonymous coding 
variant within the 3rdexon) as well as several internal bi-allelic polymorphisms (16-18). The 
protein products of DEFA1A3, HNP1-3, are microbicidal peptides that are important components 
of innate immunity(20, 22-24).HNP1-3 can also act as immune modulators that chemoattract 
native T cells, immature dendritic cells and monocytes and induce the release of chemokines and 
cytokines(25).HNP1-3 is the most abundant of neutrophil granule proteins, and there is growing 
evidence to suggest that neutrophils may play important role in mediating glomerular injury in 
IgAN (26, 27). Alpha-defensins have also been suggested to play a role in the regulation of the 
complement system and pro-inflammatory cytokine production both of which have been shown 
to play important pathogenetic role in IgAN (19, 28, 29). Interestingly, the DEFA1A3CNV locus 
is located within the region of the new IgAN susceptibility locus on 8p23.1 that was first 
discovered in the Chinese population and later validated by independent studies (5, 6, 8), which, 
together with its biological functions, suggests that the DEFA1A3 CNV locus may be involved in 
IgAN development.  
 
To evaluate the role of DEFA1A3 CNV in IgAN, we performed a comprehensive association 
analysis of the DEFA1A3 CNV locus in two independent IgAN cohorts of Southern Chinese Han, 
consisting of a total of 1189 cases and 1187 healthy controls. We discovered three strong 
independent associations within the DEFA1A3 CNV locus and further demonstrated that the 
DEFA1A3 CNVs could also influence the prognosis of IgAN. As a replication, we further 
confirmed the associations in Caucasian IgAN samples.  Interestingly, we found the association 
with membranous nephropathy (MN), but not diabetic kidney disease (DKD) in Chinese 
population. 
 
Results 
Distributions of DEFA1A3 CNVs in Chinese population 
Two independent cohorts of IgAN samples were analyzed. The first cohort consisted of 197 
cases and 199 matched healthy controls in terms of age, gender and geographic origin (Southern 
Chinese Han), and the second cohort included 992 cases and 988 healthy controls that were only 
matched for geographic origin (Southern Chinese Han) (Table S1). We measured the copy 
numbers (CNs) of DEFA1, DEFA3 and DEFA1A3 (DEFA1+DEFA3) as well as the CNs of three 
bi-allelicpolymorphisms, 5bp indel (129bp vs. 124bp), 7bp duplication (282bp vs. 275bp) and the 
4bp deletion (211bpvs. 215bp) using well-established paralogue ratio test (PRT)-based methods 
(17, 30) (Fig.S1). The PRT-based methods have been shown to have much greater accuracy for 
measuring the CNs of multi-allelic CNVs, such as beta-defensins, than real-time PCR 
analysis(31, 32) and have been successfully applied for the studies of chemokines 
(CCL3L1/CCL4L1) (33),immunoglobulin-receptor (FCGR3)(34), and beta-defensins (DEFB)(31, 
35).  
The total CN of DEFA1A3 ranges from 2 to 16 copies with a median CN of 6 per genome in our 
Chinese samples (Fig. S2). The range and median CN are 0-15 and 5 copies for DEFA1, 0-5 and 
1 copy for DEFA3, 0-6 and 1 copy for 129bp, 0-14 and 5 copies for 124bp, 0-7 and 2 copies for 
282bp, 1-14 and 5 copies for 275bp, 0-7 and 1copy for 211bp, and 0-15 and 5 copies for 215bp. 
Our results are consistent with the reported median CNs of 6 in the HapMap CHB samples and 7 
in CEU [US] and ECACC [UK] samples(16, 17), but lower than the reported median CN of 9 in 
the Japanese population (the JPT samples of the HapMap project)(19). In addition, the total 
DEFA1A3CNs of the 24HapMap CHB samples measured in this study showed a near-perfect 
correlation with the sequencing read depth of these samples from the 1000 Genome Project 
(R2=0.98, P<0.0001)(Fig.S3), confirming the high accuracy of our CN measurements. 
Correlation analysis revealed that the CNs of DEFA1, 124bp, 275bp and 215bp are correlated 
with each other (P<0.0001, r>0.65) (TableS2). 
 
Association analysis of the DEFA1A3 CNVs in Chinese IgAN samples 
We tested the associations of the DEFA1A3CNVs with IgAN susceptibility using logistic 
regression analysis and by treating the two cohorts (see above) as independent samples through a 
fixed-effects meta-analysis. As demonstrated in our previous studies (36), although sub-
population structure exists between Northern and Southern Chinese Han populations, the 
samples from Southern China are genetically homogenous. No control for population 
stratification was included in our association analysis. We found highly significant associations 
for the CNs of DEFA1A3 (P=3.99×10-9, OR=0.88), DEFA1 (P=6.71×10-5, OR=0.92), DEFA3 
(P=6.55×10-8, OR=0.82), 124bp (P=2.89×10-8, OR=0.87), 275bp (P=2.51×10-7, OR=0.89) and 
211bp (P=3.50×10-16, OR=0.75) (OR per copy). Suggestive association was also observed for 
the CNs of 129bp (P=1.37×10-2, OR=0.89). These variants showed consistent association 
between the two independent cohorts without any evidence of genetic heterogeneity, and all 
results have been adjusted for age and gender (Table S3). We performed step-wise conditional 
analysis (Table 1) and found that the associations of the211bp, DEFA1A3and DEFA3CNsare 
independent. A multivariate analysis has also confirmed the independence of these three 
associations, 211bp (P=1.71×10-9, OR=0.78), DEFA1A3 (P=2.20×10-3, OR=0.93) and DEFA3 
(P=3.33×10-3, OR=0.85). All the three associations remain statistically significant after 
Bonferonni correction (0.05/9=5.56×10-3). No evidence was found for interaction among the 
three independent CNVs (data not shown). 
 
The patients carried significantly lower CNs of all the three CNVs than the controls, indicating 
that the low coy numbers of these variants have risk effect on IgAN. On average, a patient 
carries 1 copy of 211bp, 6 copies of DEFA1A3 and 1 copy of DEFA3, which are all significantly 
lower than the median CNs in the healthy controls, 2 copies of 211bp (P=3.36×10-16),7 copies of 
DEFA1A3 (P=4.74×10-8) and 1 copy of DEFA3 (P=2.56×10-4)(Table S4; Fig.1). We found that 
for each of the three CNVs, the risk is reduced progressively with the increase of CN (Fig.2). For 
211bp, individuals carrying zero copies (about 26.8% of the population) have a 5.9-fold higher 
risk than those carrying five or more copies (about 1.9% of the population)(P=2.17×10-6). For 
DEFA1A3, individuals carrying four or fewer copies (about 7.6% of the population) have a 3.8-
fold higher risk than those carrying thirteen or more copies (about 2.0% of the 
population)(P=2.13×10-4). For DEFA3, individuals carrying zero copies (about 12.5% of the 
population) have a 3.2-fold higher risk than those carrying four or more copies (about 1.5% of 
the population) (P=3.57×10-3). The multi-variant genetic score (GS) (the standardized weighted 
sum of the CNs) of the three variants (ranging from 1.35 to 19.67) (Fig.S4) also showed very 
strong association with IgAN susceptibility (P=9.56×10-20). These three variants of the 
DEFA1A3 CNV locus can explain up to 4.96% of phenotypic variance cumulatively. 
 
Analysis of clinical phenotypes and renal survival in Chinese IgAN patients 
All the 1189 IgAN patients analyzed in this study have information for clinical and pathological 
features that are summarized in Table S5. In addition, of the 1189 IgAN patients, 382 patients 
had follow-up information with a median follow-up time of 4.5 years (interquartile range, 3.8-5.4 
years). Of the 382 patients, 27 patients progressed to end stage renal disease (ESRD) 
(eGFR<15ml/min/1.73m2, or dialysis, or renal transplantation), and 9 patients were found to 
have doubling of serum creatinine after diagnosis.   
 
Interestingly, the survival analysis of renal outcomes (ESRD or doubling of serum creatinine 
after diagnosis) using Cox regression model in the 382 IgAN patients with follow-up data 
revealed a significant association of the multi-variant GS (ranging from 1.80 to 17.14) of the 
DEFA1A3 CNVs with the renal survival of IgAN (P=0.01, HR=0.79) after adjustment for known 
prognostic factors, including age, gender, proteinuria, hypertension and serum creatinine at 
biopsy(3, 37) (Table 2).We further divided all the 382 patients into five groups based on the 
quintile of their GS values and found that the patients in the 1st quintile of GS (average 
GS=3.06)showed significant worse renal survival than the patients of the 5th quintile (average 
GS=9.57) (P=0.03, HR=3.69, after adjustment for known prognostic factors) (Fig. 3; Table 2). 
Given that the GS is intrinsically correlated with the copy numbers of DEFA1A3 CNVs, our 
results have demonstrated that patients carrying low copies of DEFA1A3 CNVs have increased 
risk for poor renal outcomes. 
 
The analysis of clinical phenotypes using the multi-variant GS revealed the association of the 
DEFA1A3 CNV locus with hyperuricemia (P=0.01) andthickening of arterial wall (P=0.008). 
However, the evidence could not survive the conservative Bonferroni correction for the multiple 
testing of 15 clinical phenotypes (although they are not totally independent) (Table S6), and the 
finding needs to be confirmed by further study.  
 
DEFA1A3 CNVs as the driver of the GWAS locus on 8p23.1 
We genotyped rs2738048, the previously reported susceptible SNP on 8p23.1 by GWAS (6) in 
the same 1189 cases and 1187 controls and performed association analysis using the same 
method above. We confirmed the association of rs2738048 (P=9.58×10-4, OR=0.80) in our 
samples (Table 1), but the association was weaker than those of 211bp, DEFA1A3 and DEFA3. 
Furthermore, conditioning on the association effect of either 211bp or DEFA1A3 can fully 
abolish the association at rs2738048; whereas all the associations of the DEFA1A3CNVs 
remained highly significant after conditioning the association effect at rs2738048 (Table S7). 
Consistently, the genotypes of rs2738048 showed strong correlation with the CNs of 211bp and 
DEFA1A3 (Table S2; Fig.S5). These results clearly demonstrate that the previously reported 
association at rs2738048 is due to the association effect of the DEFA1A3CNV locus. 
 
Replication study in Caucasian IgAN and Chinese non-IgAN renal disease samples 
As a replication, we investigated the associations of 211bp, DEFA1A3 and DEFA3 copy 
numbers in a Caucasian IgAN cohort of 531 cases and 198 controls. Both DEFA1A3 (P = 4.42 × 
10−4; OR, 0.82) and DEFA3 (P = 4.30 × 10−3; OR, 0.74) showed significant associations in the 
Caucasian cohort with consistent genetic effects as in the Chinese cohort (Table 3). However, 
211bp was much rarer in the Caucasian population, and consequently, the association of 211bp 
did not reach statistical significance (P = 7.56 × 10−2), although its genetic effect was consistent 
between Caucasian (OR, 0.79) and Chinese samples (OR, 0.75) (Table 3 and fig. S6). 
 
To evaluate whether the association effects of DEFA1A3 CNVs (211bp, DEFA1A3 and DEFA3) 
are unique to IgAN, we further investigated the associations in two Chinese cohorts of non-IgAN 
renal disease, diabetic kidney disease (DKD) (806 cases and 786 age and gender-matched 
controls) and membranous nephropathy (MN) (493 cases and 500 age and gender-matched 
controls). Interestingly, we detected the significant association of the copy number of 211bp 
variant with MN (P=1.11×10-7, OR=0.74 per copy), but did not observe any association of 
DEFA1A3 CNVs with DKD (Table 3).   
 
Association analysis of DEFA1A3 CNVs with HNP1-3 and IgA1 protein expression levels 
To investigate the effect of DEFA1A3 CNVs on HNP1-3 expression, we first measured the copy 
numbers of the DEFA1A3 CNVs (211bp, DEFA1A3 and DEFA3) as well as the serum and urine 
protein (HNP1-3) levels of DEFA1A3 in 96 IgAN patients and 62 healthy controls. There were 
no differences in the copy number distributions of DEFA1A3 CNVs between the e patients and 
controls (Wilcoxon test P>0.05). In both serum and urine, the protein levels of HNP1-3 were 
significantly higher in the patients than the healthy controls (P<0.001) (Fig.4), which is 
consistent with the fact that mature HNP1-3 are largely produced by activated neutrophils as 
inflammation response (20).  However, we could not find any association between DEFA1A3 
CNVs and protein levels of either serum HNP1-3 or urine HNP1-3 (Table S8).  In addition, we 
also performed an in vitro protein analysis of HNP1-3 in neutrophils isolated from 83 IgAN 
patients and 79 health controls after stimulating neutrophils by lipopolysaccharide (LPS). While 
there are no differences in DEFA1A3 copy number distributions between these patients and 
controls (Wilcoxon test P>0.05), the extracellular HNP1-3 levels were significantly lower in 
neutrophils isolated from the patients than the ones from controls (P=0.006), after a stimulation 
by LPS (100ng/ml for 6 hours) (Fig.4). However, we did not detect the association between 
DEFA1A3 CNVs and extracellular HNP1-3 level released by neutrophils after stimulation of 
LPS.  
 
Since the formation of the galactose-deficient IgA1-containing immune complexes is the key 
pathogenic factor contributing to the development of IgAN(38), we also investigated the effects 
of DEFA1A3 CNVs on the expression levels of serum IgA1 and galactose-deficient IgA1 in 96 
IgAN patients and 62 controls.  As expected, serum levels of IgA1 and galactose-deficient IgA1 
were both significantly higher in the IgAN patients than the health controls  (P<0.01) (Fig.S7). 
Although there were no significant evidences for individual DEFA1A3 CNVs, the multi-variant 
GS of these variants did show significant negative association with the serum levels of both IgA1 
(P=0.02) and galactose-deficient IgA1 (P=0.03) (Table 4). 
 
Discussion 
Our current study has discovered three independent risk factors for IgAN within the DEFA1A3 
CNV locus, the CNs of DEFA1A3, DEFA3 and 211bp by analyzing two independent Chinese 
IgAN samples and further confirming the associations in a Caucasian IgAN cohort.  Although 
each extra copy of these CNVs is only associated with moderate reduction of IgAN risk (by 12 to 
25%), the overall impact of the whole DEFA1A3 CNV locus is very strong, because each person 
can carry multiple copies of these variants. By explaining 4.96 % of risk variance (much higher 
than any previously reported SNPs), the DEFA1A3 CNV locus is the strongest genetic 
susceptibility factor that has been discovered for IgAN so far. Interestingly, our study has also 
revealed that the low copy number of DEFA1A3 CNV is associated with poor renal survival of 
IgAN as well as higher expression of galactose-deficient IgA1, a known pathogenic risk factor 
for IgAN.  Consistently, our analysis of HNP1-3 expressions has also demonstrated that HNP1-3 
expression will be elevated as inflammation response as seen in the serum and urine samples of 
patients, and study has demonstrated that the low copy number of the DEFA1A3 CNV is 
associated with the neutrophils from health individuals produce more HNP1-3 than IgAN 
patients when they are stimulated by LPS.  Taken together, our genetic and expression analysis 
results have suggested that HNP1-3 provide protective effect against IgAN development and the 
progression of renal dysfunction.   
 
Our study has also revealed a strong association of the DEFA1A3 CNV (211bp) with 
membranous nephropathy, but not diabetic kidney disease, although our diabetic kidney disease 
cohort had a bigger sample size and thus more power than did the membranous nephropathy 
cohort to detect the association. The genetic effect (OR) of 211bp was consistent between 
membranous nephropathy (OR, 0.74) and IgAN (OR, 0.75) without evidence of heterogeneity (I2 
= 0; Q test = 0.84), suggesting the shared protective effect of 211bp variant against both 
membranous nephropathy and IgAN. Both IgAN and membranous nephropathy are common 
causes of primary glomerulonephritis, and both are mediated by immune complexes. In contrast, 
diabetic kidney disease is a chronic microvascular complication of diabetes due to metabolic 
dysregulation (35). Although the precise immunopathogenesis of IgAN and membranous 
nephropathy remains unclear, HLA-DQA1 has been shown to be associated with both IgAN and 
membranous nephropathy (6, 36). Together, these results suggest that there are shared 
pathogenic pathways between IgAN and membranous nephropathy and that the DEFA1A3 CNV 
locus may have a broad impact on the development of primary glomerulonephritis.  
 
It is interesting to see the independent association effect of DEFA3 CN beyond the total 
DEFA1A3 CN. While DEFA1 has been in a multi-copy array for at least 25 million years, 
DEFA3 is a more recent human-specific variant arose from DEFA1 through a non-synonymous 
coding mutation in the 3rdexon(16). Previous studies have suggested that HNP3 is generally less 
active than HNP1, although HNP3 is expressed at about twice the level of HNP1 for each of 
copy of the gene (20, 45, 46). It is also intriguing that the 211bp CN shows an independent 
association effect beyond that of the DEFA1A3 CN. The 211bp is a 4bp deletion variant (TATC) 
within the 2ndintron of DEFA1A3 first investigated by us. Its molecular function is unclear, but 
analysis by Human Splicing Finder (47) suggests that this 4bp deletion may create a new splice 
acceptor site (CAG), raising the possibility that this 4bp deletion may create another novel splice 
isoform different from the mRNAs of DEFA1 and DEFA3, which may in turn influence the 
activities of HNP1-3 protein.   
 
Our large-scale protein analysis, however, failed to reveal a direct correlation between the 
DEFA1A3 copy numbers and HNP1–3 levels in serum and urine or the production of HNP1–3 
by neutrophils upon LPS stimulation. Previous studies of DEFA1A3 expression and its 
correlation with its copy number were limited. The mRNA analysis in leukocytes and 
lymphoblastoid cell lines (16, 19) as well as plasma protein analysis in patients with severe 
sepsis did not show correlation (21),  but a small study (eight subjects) showed the correlation of 
HNP1–3 amounts inside neutrophils with the copy numbers of DEFA1A3 (18).  The lack of 
correlation between the DEFA1A3 copy numbers and protein level in serum, urine and 
neutrophils is probably due to the fact that HNP1-3 are mainly produced by bone marrow 
precursors of neutrophils in promyelocytes and early myelocytes (20).  In addition, as what have 
been demonstrated in other CNV loci (49, 50), a full understanding of the haplotype structure 
(allelic structure) of the whole DEFA1A3 CNV locus may be necessary for demonstrating the 
correlation. 
 
DEFA1A3 CNVs could potentially influence IgAN development and renal progression in several 
ways. First, as DEFA1A3 is primarily expressed in promyelocytes within bone marrow, it may 
have physiological effects on bone marrow microenvironment (39, 40). Second, recent studies of 
IgAN pathogenesis highlighted the important role of impaired immune regulation along the 
mucosa-bone marrow axis and suggested that galactose-deficient IgA1 seems to be overproduced 
in bone marrow(41-43). DEFA1A3 CNVs may influence the impaired mucosa-bone marrow axis 
through its impact on the overproduction of galactose-deficient IgA1.  Third, HNP1-3 plays a 
very important role in innate immunity, and neutrophils are the first defenders for infection. 
DEFA1A3 CNVs may influence the dysregulated mucosal immune response in IgAN by 
enhancing inflammatory signals(44).   
 
Our study has also demonstrated that the DEFA1A3 CNVs are the primary driver of the 
previously reported association within the GWAS locus on 8p23.1(6). The DEFA1A3 CNVs 
showed stronger associations than the previously reported SNP rs2738048, and conditioning on 
the effect of the DEFA1A3 CNVs can fully abolish the association at rs2738048, but not vice 
versa. So, the association at rs2738048 is secondary to the association effect of the DEFA1A3 
CNVs. While this manuscript was under preparation, a new IgAN GWAS was published online, 
revealing another independent SNP rs10086568 within the GWAS locus on 8p23.1 (9). It would 
be interesting to investigate whether the association of this SNP is also due to the effect of 
DEFA1A3CNVs in a future study.   
 
Two major limitations of this study should be noted. First, our current findings are largely of 
genetic associations. The potential mechanisms underlying the involvement of the DEFA1A3 in 
the development of IgAN are interesting and biologically plausible but do need to be elucidated 
by future functional investigations. Second, the current study did not investigate the haplotype 
structure of DEFA1A3 CNVs because current genotyping and sequencing technologies could not 
determine the haplotype structure of multiallelic CNVs with long repeats in unrelated samples. 
Rapid development of long-read next-generation sequencing analysis may offer opportunities to 
characterize the haplotype structure of DEFA1A3 CNVs and understand in detail how different 
DEFA1A3 CNVs work together to influence the level and functionality of HNP proteins and 
susceptibility to developing IgAN. 
 In summary, our study is the first to show the association of the DEFA1A3 CNV locus with 
IgAN risk and renal progression and one of the few cases where the association of a complex 
multi-allelic CNV has been demonstrated with robust evidence. Our study has clearly 
demonstrated that this multi-allelic CNV is the strongest genetic susceptibility locus for IgAN 
identified so far and may have a broad impact on the development of other inflammatory renal 
diseases.  By demonstrating its protective effect again IgAN development and renal progression, 
our study has also suggested the possibility of HNP1-3 being a novel therapeutic target and 
prognostic biomarker. 
 
 
 
Materials and Methods 
Study Design 
The objective of this study was to study the effect of the DEFA1A3 CNV locus on IgAN 
development by investigating the association between the copy number of the DEFA1A3 CNV 
locus with IgAN susceptibility and renal outcomes. First, two independent cohorts from Southern 
Chinese Han consisting of a total of 1189 IgAN cases and 1187 controls were employed for the 
association analysis. All IgAN cases were biopsy-proven. The copy numbers of DEFA1A3 CNVs 
were measured using well-established paralogue ratio test (PRT)-based method.  Second, as a 
replication, the three risk variants of DEFA1A3 CNV locus discovered in Chinese IgAN samples 
were further analyzed in additional Caucasian IgAN (531cases and 198 age-, gender-matched 
controls), Chinese DKD (806 cases and 786 age-, gender-matched controls) and Chinese MN 
(493 cases and 500 age-, gender-matched controls) cohorts using the PRT-based method.  
Clinicopathologic information and follow-up data were collected from Chinese IgAN patients to 
further assess the clinical impact of DEFA1A3 CNVs on renal progression. We also investigated 
the relationship between the DEFA1A3 CNV locus and the previously published GWAS locus 
(rs2738048) on 8q23.1 by genotyping the SNP using TaqMan SNP genotyping assay in the same 
two independent Chinese cohorts.   Last, we investigated the effects of DEFA1A3 CNVs on the 
expression of HNP1-3 and galactose-deficient IgA1. There was no randomization or blinding. 
 
Study Subjects 
All IgAN cases were histopathologically diagnosed as primary IgAN by renal biopsy according 
to the following criteria: (i) immunofluorescence showing at least 2 + (scale 0 to 3 +) mesangial 
deposition of IgA, with IgA comprising the dominant immunoglobulin deposited in the 
glomeruli, and (ii) excluding individuals with cirrhosis, Henoch-Schönleinpurpura nephritis, 
hepatitis B–associated glomerulonephritis, HIV infection and systemic lupus erythematosus. 
Clinical and pathologic information were collected at diagnosis, including blood pressure, serum 
creatinine, albumin, cholesterol, triglyceride, uric acid, serum IgA level and proteinuria. 
Pathological changes recorded included crescent, thickening of arterial wall and interstitial 
inflammation. In accordance to the Oxford Classification of IgAN, samples were graded by the 
four pathological features, mesangial hypercellularity (M), endocapillary hypercellularity (E), 
segmental glomerulosclerosis (S), and tubular atrophy/interstitial fibrosis (T), resulting in a 
MEST score.  All DKD cases were diagnosed as persistent albuminuria (>30mg/g) and/or low 
estimated glomerular filtration rate (eGFR<60m/min/1.73m2) in patients with diabetes (51). 
Diabetes was defined as fasting plasma glucose≥7.0 mmol/L and/or 2-h postprandial plasma 
glucose ≥ 11.1mmol/L, by the use of hypoglycemic agents despite fasting plasma glucose, or any 
self-reported history of diabetes. All MN cases were adult biopsy-proven idiopathic MN. All the 
healthy controls were clinically verified with normal urinalysis (without red blood cells and 
protein in urine) and normal serum creatinine levels. Gender, age, geographical origin and 
ethnicity information were collected from both cases and controls through questionnaires.All 
subjects completed awritten informed consent form, and the study protocol was approved by the 
Institutional Review Board at The First Affiliated Hospital of Sun Yat-sen University. 
 
Copy Number Measurements  
The copy numbers of DEFA1A3CNVs were measured using published methods(17, 48)which 
use paralogue ratio tests(30) to determine both the total numbers of DEFA1A3 genes, and the 
copy numbers of each of four gene variants; we have already validated the accuracy of these 
methods, including calibration against 1000 Genomes Project read-depth data(17, 48). We 
measured thetotal copy numbers of DEFA1A3 (DEFA1 + DEFA3) (by MLT1A0and DEFA4PRT) 
and the individual copy numbers ofDEFA1and of DEFA3 (by DefHae3ratio), as well as the 
allelic copy numbers of three internal bi-allelic polymorphisms; 5bp indel (129bpvs.124bp, 
measured by Indel5ratio), 7bp duplication (282bp vs. 275bp, measured by7bpdupratio) and 4bp 
deletion (211bp vs. 215bp, measured by Del4ratio) (Fig. S1). These internal variants were 
chosen for three reasons. First, as a part of PRT methodology, the measurements of allelic 
variant ratio of internal variants can help to determine the copy number more accurately(17). 
Second, previous studies have suggested that some internal variants, such as the coding variant 
DEFA1 and DEFA3, may influence the expression and functionality of HNP proteins(16). Third, 
as reported, some variants within the DEFA1A3 locus, particularly 5bp indel, show good 
correlation with major haplotype classes of DEFA1A3 locus at least in European population (48). 
In brief, we combined the information from multiplex PRTs (MLT1A0 and DEFA4 PRTs) and 
four allelic ratio measurements (DefHae3/Indel5/7bpdup/Del4) into a maximum-likelihood 
framework to assign each sample to an integer copy number for all the DEFA1A3 CNVs with 
high confidence, as described(17). 
 
These measurements were all well-established PRT-based methods as previously 
described(17)except for the Del4assay, which we developed as part of this work. The 4bp 
deletion (TATC) is a newly-characterized variant within the second intron of DEFA1A3. The 
PCR for the Del4 assaywas performed by using 1uM of the primers 
TGCTCTCATTTTTGCATTCC and NED-TTTCTCCAAAGACTTGATTCCAA and 27 cycles 
of 95°C for 30 seconds, 57°C for 30 seconds, and 68°C for 60 seconds, followed by a 70°C hold 
for 40 minutes to generate amplicon products of 211bp/215bp from 10ng genomic DNA input. 
The products were mixed with 10ul HiDi formamide with ROX-500 marker (Applied 
Biosystems) for fragment analysis using an ABI 3730xl DNA Analyzer. GeneMapper 4.1 
(Applied Biosystems) was used to extract the peak areas of the separated PCR products. The 
ratio between the211bp and 215bp products (Del4 ratio) was estimated, and the copy numbers of 
the 211bp and 215bpalleles were calculated by using this Del4 ratio and the total copy number of 
DEFA1A3. 
 
For the PRT analysis of the total number ofDEFA1A3 CNV, seven CEPH/UTAH samples were 
included as reference samples of known copy number: NA11931 (7 copies), NA07347 (8 copies), 
NA11930 (5 copies), NA11993 (7 copies), NA06993 (8 copies), NA12248 (6 copies) and 
NA12249 (8 copies).The copy numbers for these reference samples had been determined 
unequivocally in previous work, including analysis of segregation and read depth(17, 48).The 
total DEFA1A3copy numbers among the cases and controls were determined by calibration of 
MLT1A0/DEFA4 PRTs against these reference samples, and the copy numbers of the other 
variants (DEFA1 vs. DEFA3,129bp vs. 124bp,282bp vs. 275bp, and 211bp vs. 215bp) were 
determined by using the total DEFA1A3copy numbers and the ratio between the CNs of two 
variants. 
 
Genotyping Analysis of rs2738048 
Genotyping analysis of rs2738048 was performed by using the TaqMan SNP genotyping assay 
from ABI. TaqMan reactions were carried out in 5ul volumes containing 10-20ng DNA 
according to the manufacturer’s protocols. Fluorescence data were obtained in the ABI 
PRISM7900HT, and genotypes were called using SDS2.4 software (Applied Biosystems). We 
examined the clustering patterns of genotypes and confirmed them to be of good quality. 
 
Association Analysis of DEFA1A3 CNVs and rs2738048 
Frequency tables were employed to describe the distributions of the DEFA1A3 CNVs, and then 
Wilcoxon rank sum tests and Chi-square tests were used to determine the significance of the 
distribution differences in DEFA1A3 CNVs and rs2738048 between the IgAN cases and controls. 
Spearman correlation analyses were used to test the correlations between theDEFA1A3 CNVs 
and rs2738048. 
 
Two independent cohorts (Table S1) were analyzed to evaluate the associations of DEFA1A3 
CNVs and SNP rs2738048withIgAN susceptibility. First, the association analysis was performed 
using PROC LOGISTIC in SAS 9.2 software (SAS Institute), where each of the DEFA1A3 
CNVs and rs2738048 were included as univariate with adjustment by age and gender. Second, 
the results from the two cohorts were combined using fixed-effects meta-analysis in PLINK(52). 
The degree of heterogeneity was estimated using the heterogeneity index (I2) and Cochran’s Q 
test in the combined analysis. Third, conditional analyses were performed using a stepwise 
logistic regression model to find independent associations. A multivariate analysis was then 
conducted to confirm the independent associations. Interaction analysis was performed by adding 
the product term of two CNVs into the logistic regression analysis. OR values were measured as 
OR per copy of DEFA1A3 CNV. P<0.05 after Bonferroni correction for multiple testing was 
considered as statistically significant.  
 
To assess the cumulative effects of DEFA1A3 CNVs, we built a composite genetic score (GS) of 
the three risk-associated variants (DEFA1A3, DEFA3 and 211bp). To account for the different 
effect sizes of the three variants, we calculated the standardized weighted sum of their copy 
numbers where the copy number of each DEFA1A3 CNV was weighted by its predicted effect 
size (natural log of OR from multi-variant logistic regression analysis), and the sum of the 
weighted copy numbers of the three variants was then divided by the average effect size to 
rescale the score (standardization). Based on the distribution of copy numbers in the patients 
with follow-up data, we have divided the patients into five groups (quintiles). The percentage of 
the total variance explained was estimated by calculating Nagelkerke’s pseudo R2 using the fmsb 
package, from the result of entering diploid copies of independent DEFA1A3 CNVs and 
affection status into the glm function in R (v 2.15.1). 
 
Analysis of Clinical Phenotypes 
DEFA1A3 CNVs were further studied for association with clinicopathologic features. Multiple 
linear regression models were applied for the correlation analysis of quantitative phenotypes 
including natural log-transformed proteinuria and serum IgA. A binary logistic regression model 
was applied for the correlation analysis of categorical variables, such as hyperuricemia and 
thickening of arterial wall. An ordinal logistic regression model was used for analysis of degrees 
of interstitial inflammation, tubular atrophy/interstitial fibrosis. The renal survival analysis of 
DEFA1A3 CNVs was performed using univariate (for the GS only) and multivariate (GS and 
known prognostic factors) Cox regression analysis. The renal survival analysis was also 
performed using Kaplan-Meier analysis, where the patients were divided into five groups 
(quintiles) according to their GS values, and log rank test was employed to evaluate the 
differences of renal survival rates between groups. All the statistical analyses were performed 
using SPSS 16.0 software (SPSS, Chicago, IL) and SAS 9.2 software (SAS Institute). 
 
Analysis of HNP1-3 serum and urine level 
The serum and urine level of HNP1–3 were measured with the HNP1–3 ELISA Test Kit (Hycult 
biotechnology, Uden, The Netherlands) according to the manufacturer‘s instructions. Serum was 
diluted 1:50 in appropriate buffer, while urine was analyzed without dilution.  Both serum and 
urine samples were transferred in duplicate samples to microtitre plates for incubation 
procedures. Absorbance was measured at 450nm using the SpectraMaxPlus384 Microplatereader 
(Molecular devices, USA).The concentration of HNP1–3 was calculated according to the 
standard curve.  
 
Isolation, Culture and Stimulation of Human Neutrophils 
Whole blood (5 ml) was collected using EDTA-coated Vacutainer and processed immediately 
for neutrophil purification. Neutrophils were isolated by single-step centrifugation of whole 
blood onto Polymorphprep (Axis-Shield) according to the manufacturer’s recommendation. 
Neutrophils were resuspended in RPMI 1640 medium supplemented with 10% fetal bovine 
serum at a final concentration of 1 × 106/ml. The purity of the neutrophils was on average >95%. 
Trypan blue exclusion showed greater than 96% viability. Neutrophils were maintained at 37°C 
in the presence of 5% CO2 and then stimulated with LPS from Escherichia coli (100 ng/ml) 
(Sigma, catalog no. L4391) for 6 hours. Neutrophils from similar cultures not exposed to 
stimulants were used as negative controls. After incubation, cells were centrifuged, and the 
culture supernatants were stored at −80°C until use for the determination of HNP1–3. The 
concentration of HNP1–3 in culture supernatants was measured with the HNP1–3 ELISA Kit 
(Hycult Biotech) as previously described. The ratio for HNP1–3 level in stimulated supernatants 
normalized with that of negative controls was used in cell culture experiments. 
 
Analysis of serum IgA1 and galactose-deficient IgA1 levels 
Serum IgA1 and galactose-deficient IgA1 (using Helix pomatia agglutinin, HPA, a lectin that 
binds terminal GalNAc in galactose-deficient IgA1) were measured by ELISA. The serum 
samples were diluted into 1:40000 for serum IgA1 and 1: 500 for galactose-deficient IgA1. For 
the measurement of serum IgA1, a standard consisting of native IgA1 (Calbiochem) was used at 
concentrations from 600 ng/ml to 4.68 ng/ml. Rabbit anti-human IgA F(ab’)2and HRP-
labeledF(ab’)2fragment of goat IgG anti-human IgA1 were purchased from Dako and Southern 
Biotech, respectively. Neuraminidase and biotin-labeled HPA were purchased from Roche and 
Sigma, respectively. The absorbance was measured at 490nm with a SpectraMaxPlus384 
Microplatereader (Molecular devices, USA).The serum concentration of IgA1was calculated 
according to the standard curve. The relative galactose-deficient IgA1 level was calculated as the 
A490 value of HPA over the A490level of IgA1. 
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Figures:  
 
 
 
 
Fig.1. Distributions of the copy numbers of the three variants of the DEFA1A3 CNV locus 
in 1189 Chinese IgAN cases and 1187 controls 
Wilcoxon rank sum tests were used to determine the significance of the distribution difference. 
Lower copies of DEFA1A3 CNVs were more frequent in IgAN patients than controls: (A) total 
DEFA1A3; (B) DEFA3; (C) 211bp. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig.2. Distribution of OR values according to different copy numbers of the DEFA1A3 
CNVs 
 OR values were calculated from logistic regression analysis in the combined Chinese IgAN 
cohorts (1189 cases/1187 controls). The overall risk was reduced steadily with the increase of 
copy number for each variant: (A) 211bp; (B) DEFA1A3; (C) DEFA3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 3. Renal survival analyses by using the Kaplan-Meier method 
IgAN patients with follow-up data were divided into five groups based on the quintiles of genetic 
score (GS): Q1 (1st quintile), Q2 (2nd quintile), Q3 (3rd quintile), Q4 (4th quintile) and Q5 (5th 
quintile).  The percentage of event-free survival (Y axis) was plotted against the follow-up time 
(X axis) for each of the five groups. Significant difference of renal survival was observed among 
the five groups of patients with different GS (Log Rank P=0.0008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4. Serum, urine and neutrophil level of HNP1-3: (A) Serum HNP1-3; (B) Urine HNP1-
3; (C) Extracellular HNP1-3 in isolated neutrophils after stimulation of LPS 
Wilcoxon rank sum tests were used to determine the significance of the expression differences. 
Serum and urine level of HNP1-3 were both significantly higher in IgAN patients (P<0.001), 
while extracellular level of HNP1-3 in isolated neutrophils after stimulation of LPS was 
significantly lower in IgAN patients (P<0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Logistic regression analysis of DEFA1A3 CNVs and rs2738048 in combined 
Chinese IgAN cohort 
 Unconditional b  Condition on  
211bp 
 Condition on  
DEFA1A3 &211bp 
 Multivariate analysis 
Variable  P OR (95%CI) a  P OR (95%CI) a  P OR (95%CI) a  P OR (95%CI) a 
DEFA1A3  3.99×10-9 0.88(0.84,0.92)  3.07×10-3 0.93(0.89,0.98)     2.20×10-3,  0.93(0.88, 0.97) 
DEFA1 6.71×10-5 0.92(0.88,0.96)  NS   NS     
DEFA3  6.55×10-5 0.82(0.76,0.88)  1.35×10-3 0.85(0.77,0.94)  3.14×10-3 0.86(0.78,0.95)  3.33×10-3 0.86(0.77,0.95) 
129bp 1.37×10-2 0.88(0.80,0.99)  NS   NS     
124bp 2.89×10-8 0.87(0.82,0.91)  3.07×10-2 0.94(0.89,0.99)  NS     
275bp 2.51×10-7 0.89(0.83,0.91)  NS   NS     
211bp  3.50×10-16 0.75(0.70,0.80)        1.71×10-9 0.78(0.72,0.84) 
rs2738048 9.58×10-4 0.80(0.70,0.92)  NS   NS     
a: OR per copy of CNV 
b: from the meta-analysis of the two independent cohorts 
NS: not significant, P≥0.05. 
 
 
 
  
 Table2.  Survival analysis of the Genetic Score of the DEFA1A3 CNVs in Chinese IgAN 
 Univariate  Multivariatea 
 HR (95%CI) P-value  HR(95%CI) P-value 
Genetic Score 0.78 (0.66,0.92) 0.004  0.79 (0.66,0.95) 0.012 
Quintile of Genetic Score  0.003   0.005 
Q5 (n=84, average GS=9.57) 1 (Ref)   1 (Ref)  
Q4 (n=71, average GS=7.22) 1.21 (0.30,4.83) 0.790  0.51 (0.11,2.33) 0.388 
Q3 (n=76, average GS=5.95) 1.41 (0.38,5.27) 0.606  1.08 (0.29,4.06) 0.912 
Q2 (n=82, average GS=4.52) 2.08 (0.63,6.91) 0.232  1.25 (0.37,4.25) 0.722 
Q1 (n=69, average GS=3.06) 5.60 (1.84,17.05) 0.002  3.69 (1.16,11.82) 0.028 
a: multivariate analysis adjusted for age, gender, proteinuria, hypertension and serum creatinine at biopsy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table3. Logistic regression analysis of DEFA1A3 CNVs in Caucasian IgAN, Chinese DKD 
and MN cohorts 
 
 Caucasian IgAN cohort 
(531 cases/198 controls) 
 Chinese DKD cohort 
(806 cases/786 controls) 
 Chinese MN cohort 
(493 cases/500 controls) 
Variant P OR (95%CI)a  P OR (95%CI)a  P OR (95%CI)a 
DEFA1A3 4.42×10-4 0.82(0.74,0.92)  4.48×10-1 0.98(0.94,1.03)  8.76×10-1 1.00(0.94,1.07) 
DEFA3 4.30×10-3 0.74(0.60,0.91)  7.78×10-1 0.99(0.89,1.09)  6.50×10-2 1.16(0.99,1.35) 
211bp 7.56×10-2 0.79(0.61,1.02)  1.58×10-1 0.94(0.87,1.02)  1.11×10-7 0.74(0.67,0.83) 
a: OR per copy of CNV . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table4. Multivariate linear regression analysis between serum IgA1, galactose-
deficient IgA1 and DEFA1A3 CNVs in 158 subjects 
a  The dependent variable in the analysis was the natural logarithmic transformed value of galactose-deficient 
IgA1 
b The dependent variable in the analysis was the square root transformed value of serum IgA1 
β c Standardized β 
 
 
 Galactose-deficient IgA1 a  Serum IgA1 b 
 Model 1   Model 2   Model 3  Model 4 
Variables  β c P  β c P  β c P  β c P 
DEFA1A3 copies -0.12 0.20     -0.13 0.16    
DEFA3 copies -0.09 0.26     -0.13 0.14    
211bp copies -0.08 0.35     -0.08 0.39    
GS    -0.17 0.03  0.26 0.002  -0.19 0.02 
Case (vs. control) 0.21 0.008  0.22 0.006     0.27 0.001 
